insights_auto
LGND 주가가 상승한 이유: 2.73%?
자세히 알아보기chevron_right
LGND:NASDAQ
리간드 제약
US$314.78
arrow_upward
+2.73%(+8.38) 1D
US$314.78
0.00% (0.00)
bedtime시간 외 거래
휴장: 10월 21일, 오후 4시 0분 1초 GMT-4 · USD
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoLGND의 주요 통계 생성 중...
시가
US$305.36
고가
US$317.64
저가
US$303.93
시가총액
62.75억
평균 거래량
25.18만
거래량
21.55만
주가수익률
33.48
52주 최고가
US$326.63
52주 최저가
US$175.89
EPS
US$9.40
베타
1.06
유통 주식수
1993.60만
직원 수
47
시가
US$305.36
고가
US$317.64
저가
US$303.93
시가총액
62.75억
평균 거래량
25.18만
거래량
21.55만
주가수익률
33.48
52주 최고가
US$326.63
52주 최저가
US$175.89
EPS
US$9.40
베타
1.06
유통 주식수
1993.60만
직원 수
47
뉴스 기사
웹 소스 및 뉴스 파트너 제공
AD HOC NEWS
·
1일 전
Barclays sets target for Ligand Pharmaceuticals stock at USD 345
프로필
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
리간드 제약에 관한 정보